Document is current
Any future updates will be listed below
-
Authors
Heredia-Pi, Ileana B. https://orcid.org/0000-0002-9998-9239
Orozco-Núñez, Emanuel https://orcid.org/0000-0002-6550-7385
Guerrero-López, Carlos M. https://orcid.org/0000-0002-6405-5217
Cerecer-Ortiz, Nadia https://orcid.org/0000-0001-5200-7894
Ojeda-Arroyo, Enai https://orcid.org/0000-0002-7188-593X
Allen-Leigh, Betania https://orcid.org/0000-0003-3200-5917
Jan, Stephen https://orcid.org/0000-0003-2839-1405
Downey, Laura https://orcid.org/0000-0002-9563-7113
Serván-Mori, Edson https://orcid.org/0000-0001-9820-8325
-
Funding
Funding for this research was provided by:
the Mexican Association of Pharmaceutical Research Industries, A.C. (2268/1772/S6-21)
- License Information
-
More Information
Article History
Received: 2 January 2025
Accepted: 15 May 2025
First Online: 30 May 2025
Declarations
:
: This study was approved by the Research, Biosafety, and Ethics Committees of the National Institute of Public Health in Mexico (ID: CI-507-2022/CB22-173).
: Not applicable.
: The authors declare no competing interests.
: We dedicate this manuscript to our colleague and friend, Sandra Sosa-Rubí, Ph.D., who passed away in March 2021. Sandra consistently inspired us in our analysis of equity and financial protection in health during her fruitful lifetime.
